Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We

Johannes Czernin1, Lisa Bodei2,3, Irvin Modlin4

  • 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; jczernin@mednet.ucla.edu.

Abstract

No abstract available in PubMed .

Related Concept Videos